8-71216733-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000503.6(EYA1):c.1319G>A(p.Arg440Gln) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 33)
Consequence
EYA1
NM_000503.6 missense
NM_000503.6 missense
Scores
9
9
1
Clinical Significance
Conservation
PhyloP100: 7.86
Genes affected
EYA1 (HGNC:3519): (EYA transcriptional coactivator and phosphatase 1) This gene encodes a member of the eyes absent (EYA) family of proteins. The encoded protein may play a role in the developing kidney, branchial arches, eye, and ear. Mutations of this gene have been associated with branchiootorenal dysplasia syndrome, branchiootic syndrome, and sporadic cases of congenital cataracts and ocular anterior segment anomalies. A similar protein in mice can act as a transcriptional activator. Alternatively spliced transcript variants have been identified for this gene. [provided by RefSeq, Dec 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.949
PP5
Variant 8-71216733-C-T is Pathogenic according to our data. Variant chr8-71216733-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 7935.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr8-71216733-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
EYA1 | NM_000503.6 | c.1319G>A | p.Arg440Gln | missense_variant | 14/18 | ENST00000340726.8 | NP_000494.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EYA1 | ENST00000340726.8 | c.1319G>A | p.Arg440Gln | missense_variant | 14/18 | 1 | NM_000503.6 | ENSP00000342626.3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome Cov.: 33
GnomAD4 exome
Cov.:
33
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:8
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Branchiootorenal syndrome 1 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 1997 | - - |
Pathogenic, criteria provided, single submitter | research | Center for Statistical Genetics, Columbia University | Nov 08, 2024 | - - |
Branchiootic syndrome 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Aug 02, 2022 | - - |
EYA1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 03, 2024 | The EYA1 c.1319G>A variant is predicted to result in the amino acid substitution p.Arg440Gln. This variant is also referred to as c.1220G>A or R407Q in the literature, corresponding to NM_172060. It has been reported in individuals with branchio-oto-renal syndrome (see, for example, Kumar et al. 1997. PubMed ID: 10464653; Orten et al. 2008. PubMed ID: 18220287; Mann et al. 2019. PubMed ID: 30655312), including some in whom it was reported de novo (Masuda et al. 2022. PubMed ID: 35046468; Cho et al. 2024. PubMed ID: 39125727). An in vivo experimental study indicated this variant affected development of the otic vesicle and vestibulocochlear nerve in Xenopus laevis embryos (referred to as R435Q, Li et al. 2010. PubMed ID: 19951260). An additional study indicated this variant protein was able to translocate into the nucleus with similar efficiency to wild type (Musharraf et al. 2014. PubMed ID: 24489909). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic. - |
Branchiooculofacial syndrome Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | Yale Center for Mendelian Genomics, Yale University | Jan 17, 2019 | - - |
Melnick-Fraser syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 18, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 440 of the EYA1 protein (p.Arg440Gln). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with branchiootorenal syndrome (PMID: 10464653, 15146463, 18220287, 21280147, 28832562). This variant is also known as c.1220G>A (p.Arg407Gln). ClinVar contains an entry for this variant (Variation ID: 7935). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt EYA1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects EYA1 function (PMID: 19951260, 24489909). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Rare genetic deafness Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | May 19, 2011 | - - |
Branchiootic syndrome 1;C3714941:Otofaciocervical syndrome 1;C4551702:Branchiootorenal syndrome 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2+PS4+PP1_Strong+PM1+PS3_Moderate+PP3 - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Uncertain
D;D;D;.;.;.;D;D;.;.;.;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
.;.;.;D;D;D;.;D;D;D;D;D;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;M;M;.;.;.;M;M;.;.;.;.;.
PrimateAI
Pathogenic
D
PROVEAN
Uncertain
D;.;D;D;D;D;.;.;.;.;.;D;D
REVEL
Pathogenic
Sift
Uncertain
D;.;D;D;D;D;.;.;.;.;.;D;D
Sift4G
Uncertain
D;.;D;D;D;D;.;.;.;.;.;D;D
Polyphen
D;D;D;.;D;D;D;D;.;.;.;.;.
Vest4
MutPred
Loss of MoRF binding (P = 0.0666);Loss of MoRF binding (P = 0.0666);Loss of MoRF binding (P = 0.0666);.;.;.;Loss of MoRF binding (P = 0.0666);Loss of MoRF binding (P = 0.0666);.;.;.;.;.;
MVP
MPC
0.73
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DG_spliceai
Position offset: -1
DS_DL_spliceai
Position offset: -41
Find out detailed SpliceAI scores and Pangolin per-transcript scores at